JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


First published online June 13, 2008
J Nucl Med 2008, doi:10.2967/jnumed.108.051474
© 2008 by Society of Nuclear Medicine
This Article
Right arrow Full Text (Publish Ahead of Print[PDF])
Right arrow All Versions of this Article:
jnumed.108.051474v1
49/7/1183    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Mihara, T.
Right arrow Articles by Matsuoka, N.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mihara, T.
Right arrow Articles by Matsuoka, N.


Brain Adenosine A2A Receptor Occupancy by a Novel A1/A2A Receptor Antagonist, ASP5854, in Rhesus Monkeys: Relationship to Anticataleptic Effect

Takuma Mihara 1*, Akihiro Noda 2, Hiroshi Arai 3, Kayoko Mihara 1, Akinori Iwashita 1, Yoshihiro Murakami 2, Takahiro Matsuya 2, Sosuke Miyoshi 2, Shintaro Nishimura 2, and Nobuya Matsuoka 1

1 Pharmacology Research Laboratories, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan
2 Applied Pharmacology Research Laboratories, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan
3 Drug Metabolism Research Laboratories, Astellas Pharma Inc., Azusawa, Tokyo, Japan

* To whom correspondence should be addressed. E-mail: takuma.mihara{at}jp.astellas.com.


   Abstract

The purpose of the present study was to measure adenosine A2A receptor (A2AR) occupancy in the brain by a novel adenosine A1/A2A antagonist, 5-[5-amino-3-(4fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), and to determine the degree of receptor occupancy necessary to inhibit haloperidol-induced catalepsy in rhesus monkeys. Methods: A2AR occupancy by ASP5854 (0.001–0.1 mg/kg) was examined in the striatum using an A2AR-specific radiotracer, 11C-SCH442416, and PET in conscious rhesus monkeys. A2AR occupancy was monitored after a single intravenous administration of ASP5854 in 3 animals, and a dynamic PET scan was performed at 1, 4, and 8 h after an intravenous bolus injection of the tracer for approximately 740 MBq. Catalepsy was induced by haloperidol (0.03 mg/kg, intramuscularly) and examined for incidence and duration. Results: ASP5854 dose-dependently increased A2AR occupancy in the striatum and showed long-lasting occupancy even after the reduction of plasma concentration. Haloperidol induced severe catalepsy at 40 min after intramuscular injection. The incidence and duration of cataleptic posture were dose-dependently reduced by ASP5854 at 1 h after oral administration, and the minimum ED50 value was 0.1 mg/kg. Administration of a dose of 0.1 mg/kg yielded a plasma concentration of 97 ± 16.3 ng/mL, which corresponded to 85%–90% of A2AR occupancy. Conclusion: These results showed that ASP5854 antagonized A2AR in the striatum, and the dissociation from A2AR was relatively slow. In addition, more than 85% A2AR occupancy by ASP5854 resulted in an inhibition of haloperidol-induced catalepsy. Thus, such a pharmacodynamic study directly demonstrates both the kinetics of a drug in the brain and the relationship between dose-dependent receptor occupancy and plasma level.

Key Words: PET, ASP5854, 11C-SCH442416, catalepsy, adenosine A2A receptors







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2008 by the Society of Nuclear Medicine.